Physician profile
David J Jeng
NPI 1679758742
$7,257.99
in general payments reported to CMS, 2019-2025
36 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $997 · 2020: $593 · 2021: $1,451 · 2022: $785 · 2023: $983 · 2024: $1,347 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,432.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,011.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $884.33 | 2019-2023 | |
| Abbvie INC. | $764.42 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $519.30 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $397.32 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $376.63 | 2022-2024 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $355.06 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $343.15 | 2019-2022 | |
| Rxsight INC | $321.86 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Coherus Oncology, INC. | $226.08 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $207.58 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $174.96 | 2019-2021 | |
| Alcon Vision LLC | $164.82 | 2022-2025 | Rocklatan, Wavelight Refractive Suite |
| Tarsus Pharmaceuticals, INC. | $150.72 | 2024-2025 | Xdemvy |
| Sandoz INC. | $145.74 | 2024-2025 | Cimerli |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $144.02 | 2019-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $135.97 | 2024-2025 | Izervay |
| Genentech USA, INC. | $134.01 | 2021-2023 | Vabysmo |
| Integra Lifesciences Corporation | $109.41 | 2024 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Dompe US, INC. | $97.21 | 2025 | Oxervate |
| Biotissue Holdings INC. | $90.76 | 2024 | |
| Eyepoint US, INC. | $78.68 | 2019-2021 | |
| Harrow Eye, LLC | $68.16 | 2024-2025 | Vevye |
| Glaukos Corporation | $48.48 | 2024-2025 | Photrexa Viscous and Photrexa, Radius |
| Johnson & Johnson Surgical Vision, INC. | $46.87 | 2021 | |
| Shire North American Group INC | $45.18 | 2019 | |
| Ocular Therapeutix, INC. | $39.31 | 2021-2025 | Dextenza |
| Regeneron Healthcare Solutions, INC. | $28.72 | 2019-2024 | Eylea Hd |
| Eyevance Pharmaceuticals LLC | $24.75 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $23.91 | 2025 | Purified Cortrophin Gel |
| Rayner Intraocular Lenses Limited | $18.39 | 2022 | |
| Janssen Biotech, INC. | $17.84 | 2025 | Tremfya |
| Thea Pharma INC. | $17.32 | 2023 | |
| Amgen INC. | $16.48 | 2024 | Tepezza |
| Sight Sciences, INC. | $15.70 | 2019 | |
| Coopervision INC. | $13.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jeng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.